Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.
A Phase I trial of 22 patients with metastatic prostate cancer showed that the alpha-emitting radiopharmaceutical therapy ²¹²Pb-ADVC001 was well tolerated, with no serious adverse events reported. The therapy, targeted to prostate-specific membrane antigen (PSMA), resulted in PSA levels declining by at least 50% in 80% of patients and a median radiographic progression-free survival of 11.2 months.
With an overall response rate of 100%, the study authors believe further clinical development of ²¹²Pb-ADVC001 could address unmet needs in treating metastatic prostate cancer, particularly for patients resistant to beta-emitting radiopharmaceuticals.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- New treatment approach shows promise in reducing prostate cancer spread medicalxpress.com
